Misplaced Pages

Rezvilutamide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Rezvilutamide
Clinical data
Other namesSHR3680
Drug classNonsteroidal antiandrogen
Identifiers
IUPAC name
  • 4-phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H20F3N3O4S
Molar mass479.47 g·mol
3D model (JSmol)
SMILES
  • CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC(CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI
  • InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1
  • Key:KRBMOYIWQCZVHA-INIZCTEOSA-N

Rezvilutamide (INNTooltip International Nonproprietary Name), sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer. It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide. The drug was developed by Jiangsu Hengrui Medicine. Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.

References

  1. "Rezvilutamide". chemidplus. U.S. National Library of Medicine.
  2. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO.
  3. ^ "SHR 3680". AdisInsight.
  4. Keam SJ (January 2023). "Rezvilutamide: First Approval". Drugs. 83 (2): 189–193. doi:10.1007/s40265-022-01831-y. PMID 36630077. S2CID 255593586.
  5. ^ Qin X, Han W, Luo H, Du C, Zou Q, Sun Z, et al. (2020). "SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study". Journal of Clinical Oncology. 38 (6_suppl): 90. doi:10.1200/JCO.2020.38.6_suppl.90. S2CID 214027454.
Androgen receptor modulators
ARTooltip Androgen receptor
Agonists
SARMsTooltip Selective androgen receptor modulator
Antagonists
GPRC6A
Agonists
See also
Receptor/signaling modulators
Androgens and antiandrogens
Estrogen receptor modulators
Progesterone receptor modulators
List of androgens and anabolic steroids


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it.

Categories: